Handbook of Clinical medicine

cin 5mg/24h (max 10mg); oxyb utynin, drowsiness, constipation, tachycardia, but more SE unless transdermal route or modi- abdominal pain, urinary retention, fi ed release used; trospium or feso t erodine sinusitis, oedema, weight, glaucoma (prefers M3 receptors). Avoid in myasthenia, precipitation. Up to 4mg/12h may be and if glaucoma or UC are uncontrolled. needed (unlicensed). Topical oestrogens Post-menopausal urgency, frequency + noc- turia may occasionally be improved by raising the bladder’s sensory threshold. Systemic therapy worsens incontinence. 3 adrenergic agonist: mirabegron Consider if antimuscarinics are contrain- 50mg/24h; SE tachycardia; CI: severe HTN; dicated or clinically ineff ective, or if SE Caution if renal/hepatic impairment. unacceptable. Intravesical botulinum toxin (Botox®) Consider if above medications ineff ective. Percutaneous posterior tibial nerve Consider if drug treatment ineff ective and stimulation (PTNS). (A typical treatment Botox® not wanted. PTNS delivers neuromodu- consists of ≈12 weekly 30 min sessions.) lation to the S2–S4 junction of the sacral nerve plexus. Neuromodulation via transcutaneous Sacral nerve stimulation inhibits the refl ex electrical stimulation behaviour of involuntary detrusor contractions. Modulation of aff erent input from Gabapentin (unlicensed). bladder Hypnosis, psychotherapy, bladder (These all require good motivation.) training* Surgery (eg clam ileocystoplasty) Reserved for troublesome or intractable symptoms. The
